Search clinical trials for: T2 - Low dose of BI 655130

Total 1103 results

Boehringer Ingelheim

Completed

A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body

Healthy

Belgium
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male Volunteers

Healthy

Belgium
AbbVie
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

Psoriasis

United States, Germany, United Kingdom
Boehringer Ingelheim

Completed

BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Relative Oral Bioavailability of BI 44847 as Suspension Compared to Tablet and the Influence of Food Anf of BI 44847 as Solution Compared to Tablet in Healthy Male Volunteers

Healthy
Boehringer Ingelheim
Eli Lilly and Company

Completed

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czech Republic, Denmark, Estonia, France, Georgia, Greece, Hong Kong, Hungary, India, Indonesia, Israel, Italy, Japan, Korea, Republic of, Malaysia and more
Boehringer Ingelheim

Completed

Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers

Healthy
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Denmark, Estonia, Hungary, Italy, Lebanon, Malaysia, Mexico, Peru, Philippines, Poland, Romania, Russian Federation, Spain, Sweden, Taiwan
Boehringer Ingelheim

Completed

Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial

Hepatitis C

Japan
Boehringer Ingelheim

Completed

4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

Hepatitis C, Chronic

France, Germany, Switzerland
Boehringer Ingelheim

Completed

Bioavailability of Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Solution Formulation in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Denmark, France, Ireland, Korea, Republic of, Portugal, United Kingdom
Boehringer Ingelheim

Completed

Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS

Healthy
Boehringer Ingelheim

Completed

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

Hepatitis C, Chronic

United States, Germany, Spain, United Kingdom
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Canada, China, France, Germany, India, Korea, Republic of, Mexico, Slovakia, Slovenia, Taiwan, Turkey
Boehringer Ingelheim

Completed

BI 44370 TA in Acute Migraine Attack

Migraine Disorders

Belgium, El Salvador, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom
Boehringer Ingelheim

Completed

BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Boehringer Ingelheim

Completed

Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Liver Diseases | Healthy
Postgraduate Institute of Medical Education and...

Completed

Utility of LDCT in Lung Cancer Screening in a TB Endemic Region

Lung Cancer

India
Boehringer Ingelheim

Completed

Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects

Healthy
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Boehringer Ingelheim

Completed

4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)

Diabetes Mellitus, Type 2

Japan
Boehringer Ingelheim

Completed

Effects of BI 44370 TA Orally Applied as Tablets on the Pharmacokinetics of Orally Administered Midazolam Solution in Healthy Volunteers

Healthy
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer

Lung Carcinoma

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Boehringer Ingelheim

Completed

Pharmacokinetics and Pharmacodynamics of Multiple 5 mg Doses of BI 1356 p.o. Given Once Daily Compared to Multiple 2.5 mg Doses Given Twice Daily in Healthy Male and Female Volunteers

Healthy
Fu-Sheng Wang

Unknown

Umbilical Cord Mesenchymal Stem Cells for Immune Reconstitution in HIV-infected Patients

Human Immunodeficiency Virus | Disorder of Immune Reconstitution

China
University of Roehampton

Recruiting

The Effect of a Botanical Plant Extract on Gut Health, Immunity and Metabolic Disorders in Healthy Adults (GHIMD)

Healthy

United Kingdom
Biocity Biopharmaceutics Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease

Diabetic Kidney Disease | IgA Nephropathy

China
Bruckner Oncology

Completed

Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer

Pancreatic Cancer

United States
Swedish University of Agricultural Sciences
Uppsala University

Completed

The Effect of Dietary Fibre and Plant Protein on Appetite and Metabolic Function

Appetite Regulation

Sweden
Presidio Pharmaceuticals, Inc.
Boehringer Ingelheim

Completed

Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

Chronic Hepatitis C

United States
Medical University of Warsaw

Recruiting

High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety

Peanut Allergy

Poland
Hernando Gomez
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...

Enrolling by invitation

Safety and Feasibility of Metformin for Sepsis Induced AKI

Sepsis | Septic Shock | Acute Kidney Injury | Metformin

United States
Virchow Group
Adocia

Completed

Comparative Study of 3 Dose Regimens of BioChaperone to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer

Diabetic Foot Ulcers

India
Xin Zeng

Recruiting

Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis (RPPCLC)

Decompensated Cirrhosis

China
Boehringer Ingelheim

Completed

Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female Subjects

Healthy

Germany
Tampere University Hospital
Deaconess Foundation; A-Clinic Foundation

Recruiting

A Cross-Sectional Observational Study on Retained Drug Needle Fragments in People Who Use Intravenous Drugs

Soft Tissue Injuries | Substance Dependence | Foreign Bodies | Drug Abuse, Intravenous | Needle Injury

Finland
Assistance Publique - Hôpitaux de Paris
National Cancer Institute, France; Ministère de la Santé et des Solidarités

Recruiting

Lung Cancer Screening With Low-dose CT Scan in Women : Implementation Study (CASCADE)

Lung Cancer Screening

France
AIM Vaccine Co., Ltd.
Shulan (Hangzhou) Hospital; Yuncheng Central Hospital

Active, not recruiting

Clinical Trial of SARS-CoV-2 mRNA Vaccine in China

COVID-19

China
Duke University

Completed

Low Dose CT Distal Radius Fractures

Radius Fractures

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...
Netherlands Organisation for Scientific Research; Aspen Pharma; CHU of Saint... and other collaborators

Completed

Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy (Highlow)

Pulmonary Embolism | Deep Venous Thrombosis

Norway, Netherlands, Denmark, France, Belgium, Ireland, United States, Canada, Russian Federation, Spain
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat® Soft MistTM Inhaler B in Healthy Male Volunteers

Healthy
Shineway Pharmaceutical Co.,Ltd

Unknown

The Clinical Trial of Chinese Herbal Medicine SaiLuoTong Capsule

Vascular Dementia

China
Jiangsu Province Centers for Disease Control and...
Beijing Institute of Biotechnology; Tianjin Cansino Biotechnology Inc

Completed

A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.

Ebola Virus Disease

China

3

Subscribe